USP22 promotes the proliferation of hepatocellular carcinoma cells via deubiquitinating and stabilising cyclin‐dependent kinase CDK11B, and it inhibits Sorafenib‐induced ferroptosis by decreasing H2BK120ub occupancy at TFRC TSS downstream region. Here, CDK11B is linked to hepatocellular carcinoma.